.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
ZeroHarm Sciences recently raised Rs 65 crore to scale its innovative plant-based nutraceutical brand. Consequently, this capital infusion from Kotak Life Sciences Fund and Alkemi Growth Capital marks a major milestone. The company intends to enhance its research capabilities and global reach.
Specifically, ZeroHarm uses proprietary nano-formulation technology to increase the bioavailability of its supplements. This method ensures that herbal actives are absorbed more effectively by the body. Furthermore, the firm is building India's first \"Trust over Promise\" health platform. This model correlates supplement use with measurable diagnostic results.
Additionally, the startup plans to enter markets in the US, UK, and the Middle East. ZeroHarm maintains a vertically integrated ecosystem, covering extraction, R&D, and manufacturing. Notably, this structure allows for strict quality control and standardized health outcomes. Because of these factors, investors see high potential in the company’s science-led approach.
Q1: What is the \"Trust over Promise\" platform?
The \"Trust over Promise\" platform allows customers to see measurable health outcomes through before-and-after diagnostic testing.
Q2: How does nano-formulation technology benefit patients?
Nano-formulation breaks down herbal actives into ultra-fine particles, which significantly improves their absorption and efficacy compared to traditional supplements.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
ZeroHarm Sciences raised Rs 65 crore to expand its plant-based nutraceutical brand using nano-technology and a diagnostic-led health outcome model....
7 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
